Research progress in fecal microbiota transplantation in hepatobiliary and pancreatic surgery

doi:10.3877/cma.j.issn.2095-3232.2025.04.023

Abstract

Abstract:

The imbalance of gut microbiota is closely correlated with the incidence, development and prognosis of hepatobiliary and pancreatic diseases, which can cause the imbalance of gut microbiota. These two events affect and interact with each other. Fecal microbiota transplantation (FMT) is a promising method to reconstruct gut microbiota and improve prognosis of hepatobiliary and pancreatic diseases. In recent years, FMT has received widespread attention in multiple clinical trials, and has been gradually applied in clinical research of hepatobiliary and pancreatic diseases. In this article, the relationship between gut microbiota and hepatobiliary and pancreatic diseases was illustrated, and research progress in the application of FMT in hepatobiliary and pancreatic diseases was summarized.

Key words: Fecal microbiota transplantation, Liver diseases, Intestinal microbiota, Gut-liver axis, Nonalcoholic fatty liver disease (NAFLD)

Yongfei1 He, Jicai Wang, Fenfang1 Wu, Xianjie Shi. Research progress in fecal microbiota transplantation in hepatobiliary and pancreatic surgery[J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2025, 14(04): 646-653.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhgzwkssxdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3232.2025.04.023

https://zhgzwkssxdzzz.cma-cmc.com.cn/EN/Y2025/V14/I04/646

References 87

[1]	Allegretti JR, Mullish BH, Kelly C, et al. The evolution of the use of faecal microbiota transplantation and emerging therapeutic indications[J]. Lancet, 2019, 394(10196): 420-431. DOI: 10.1016/S0140-6736(19)31266-8.
[2]	David LA, Maurice CF, Carmody RN, et al. Diet rapidly and reproducibly alters the human gut microbiome[J]. Nature, 2014, 505(7484): 559-563. DOI: 10.1038/nature12820.
[3]	Illiano P, Brambilla R, Parolini C. The mutual interplay of gut microbiota, diet and human disease[J]. FEBS J, 2020, 287(5): 833-855. DOI: 10.1111/febs.15217.
[4]	Motiani KK, Carmen Collado M, Eskelinen JJ, et al. Exercise training modulates gut microbiota profile and improves endotoxemia[J]. Med Sci Sports Exerc, 2020, 52(1): 94-104. DOI: 10.1249/MSS.0000000000002112.
[5]	Walrath T, Dyamenahalli KU, Hulsebus HJ, et al. Age-related changes in intestinal immunity and the microbiome[J]. J Leukoc Biol, 2021, 109(6): 1045-1061. DOI: 10.1002/JLB.3RI0620-405RR.
[6]	Hoefert B. über die bakterienbefunde im duodenalsaft von gesunden und kranken[J]. Zschr Klin Med, 1921, 92, 221-235.
[7]	Zeng Y, Chen S, Fu Y, et al. Gut microbiota dysbiosis in patients with hepatitis B virus-induced chronic liver disease covering chronic hepatitis, liver cirrhosis and hepatocellular carcinoma[J]. J Viral Hepat, 2020, 27(2): 143-155. DOI: 10.1111/jvh.13216.
[8]	Schwan A, Sjölin S, Trottestam U, et al. Relapsing Clostridium difficile enterocolitis cured by rectal infusion of homologous faeces[J]. Lancet, 1983, 2(8354): 845. DOI: 10.1016/s0140-6736(83)90753-5.
[9]	Wu Z, Zhang B, Chen F, et al. Fecal microbiota transplantation reverses insulin resistance in type 2 diabetes: a randomized, controlled, prospective study[J]. Front Cell Infect Microbiol, 2023, 12: 1089991. DOI: 10.3389/fcimb.2022.1089991.
[10]	Pande A, Sharma S, Khillan V, et al. Fecal microbiota transplantation compared with prednisolone in severe alcoholic hepatitis patients: a randomized trial[J]. Hepatol Int, 2023, 17(1): 249-261. DOI: 10.1007/s12072-022-10438-0.
[11]	Routy B, Lenehan JG, Miller WH Jr, et al. Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial[J]. Nat Med, 2023, 29(8): 2121-2132. DOI: 10.1038/s41591-023-02453-x.
[12]	Gill SR, Pop M, Deboy RT, et al. Metagenomic analysis of the human distal gut microbiome[J]. Science, 2006, 312(5778): 1355-1359. DOI: 10.1126/science.1124234.
[13]	Salvucci E. The human-microbiome superorganism and its modulation to restore health[J]. Int J Food Sci Nutr, 2019, 70(7): 781-795. DOI: 10.1080/09637486.2019.1580682.
[14]	Kastl AJ Jr, Terry NA, Wu GD, et al. The structure and function of the human small intestinal microbiota: current understanding and future directions[J]. Cell Mol Gastroenterol Hepatol, 2020, 9(1): 33-45. DOI: 10.1016/j.jcmgh.2019.07.006.
[15]	Visconti A, Le Roy CI, Rosa F, et al. Interplay between the human gut microbiome and host metabolism[J]. Nat Commun, 2019, 10(1): 4505. DOI: 10.1038/s41467-019-12476-z.
[16]	Postler TS, Ghosh S. Understanding the holobiont: how microbial metabolites affect human health and shape the immune system[J]. Cell Metab, 2017, 26(1): 110-130. DOI: 10.1016/j.cmet.2017.05.008.
[17]	Tripathi A, Debelius J, Brenner DA, et al. The gut-liver axis and the intersection with the microbiome[J]. Nat Rev Gastroenterol Hepatol, 2018, 15(7): 397-411. DOI: 10.1038/s41575-018-0011-z.
[18]	Sidhu M, van der Poorten D. The gut microbiome[J]. Aust Fam Physician, 2017, 46(4): 206-211.
[19]	Gupta A, Khanna S. Fecal microbiota transplantation[J]. Jama, 2017, 318(1): 102. DOI: 10.1001/jama.2017.6466.
[20]	Cammarota G, Ianiro G, Tilg H, et al. European consensus conference on faecal microbiota transplantation in clinical practice[J]. Gut, 2017, 66(4): 569-580. DOI: 10.1136/gutjnl-2016-313017.
[21]	Zhang F, Zhang T, Zhu H, et al. Evolution of fecal microbiota transplantation in methodology and ethical issues[J]. Curr Opin Pharmacol, 2019, 49: 11-16. DOI: 10.1016/j.coph.2019.04.004.
[22]	Biazzo M, Deidda G. Fecal microbiota transplantation as new therapeutic avenue for human diseases[J]. J Clin Med, 2022, 11(14): 4119. DOI: 10.3390/jcm11144119.
[23]	Kao D, Roach B, Silva M, et al. Effect of oral capsule- vs colonoscopy-delivered fecal microbiota transplantation on recurrent Clostridium difficile infection: a randomized clinical trial[J]. JAMA, 2017, 318(20): 1985-1993. DOI: 10.1001/jama.2017.17077.
[24]	Surawicz CM, Brandt LJ, Binion DG, et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections[J]. Am J Gastroenterol, 2013, 108(4): 478-498;quiz499. DOI: 10.1038/ajg.2013.4.
[25]	de Vos WM, Tilg H, Van Hul M, et al. Gut microbiome and health: mechanistic insights[J]. Gut, 2022, 71(5): 1020-1032. DOI: 10.1136/gutjnl-2021-326789.
[26]	Halsey TM, Thomas AS, Hayase T, et al. Microbiome alteration via fecal microbiota transplantation is effective for refractory immune checkpoint inhibitor-induced colitis[J]. Sci Transl Med, 2023, 15(700): eabq4006. DOI: 10.1126/scitranslmed.abq4006.
[27]	Spreafico A, Heirali AA, Araujo DV, et al. First-in-class Microbial Ecosystem Therapeutic 4 (MET4) in combination with immune checkpoint inhibitors in patients with advanced solid tumors (MET4-IO trial)[J]. Ann Oncol, 2023, 34(6): 520-530. DOI: 10.1016/j.annonc.2023.02.011.
[28]	Yang Q, Wang B, Zheng Q, et al. A review of gut microbiota-derived metabolites in tumor progression and cancer therapy[J]. Adv Sci, 2023, 10(15): e2207366. DOI: 10.1002/advs.202207366.
[29]	Mouries J, Brescia P, Silvestri A, et al. Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development[J]. J Hepatol, 2019, 71(6): 1216-1228. DOI: 10.1016/j.jhep.2019.08.005.
[30]	Albillos A, de Gottardi A, Rescigno M. The gut-liver axis in liver disease: pathophysiological basis for therapy[J]. J Hepatol, 2020, 72(3): 558-577. DOI: 10.1016/j.jhep.2019.10.003.
[31]	Saitta C, Pollicino T, Raimondo G. Occult hepatitis B virus infection: an update[J]. Viruses, 2022, 14(7): 1504. DOI: 10.3390/v14071504.
[32]	You H, Wang F, Li T, et al. Guidelines for the prevention and treatment of chronic hepatitis B (version 2022)[J]. J Clin Transl Hepatol, 2023, 11(6): 1425-1442. DOI: 10.14218/JCTH.2023.00320.
[33]	Zhang Q, Zhou J, Zhang X, et al. Mendelian randomization supports causality between gut microbiota and chronic hepatitis B[J]. Front Microbiol, 2023, 14: 1243811. DOI: 10.3389/fmicb.2023.1243811.
[34]	Ren YD, Ye ZS, Yang LZ, et al. Fecal microbiota transplantation induces hepatitis B virus e-antigen (HBeAg) clearance in patients with positive HBeAg after long-term antiviral therapy[J]. Hepatology, 2017, 65(5): 1765-1768. DOI: 10.1002/hep.29008.
[35]	Chauhan A, Kumar R, Sharma S, et al. Fecal microbiota transplantation in hepatitis B e antigen-positive chronic hepatitis B patients: a pilot study[J]. Dig Dis Sci, 2021, 66(3): 873-880. DOI: 10.1007/s10620-020-06246-x.
[36]	Guo W, Zhou X, Li X, et al. Depletion of gut microbiota impairs gut barrier function and antiviral immune defense in the liver[J]. Front Immunol, 2021, 12: 636803. DOI: 10.3389/fimmu.2021.636803.
[37]	Wang J, Zhou X, Li X, et al. Fecal microbiota transplantation alters the outcome of hepatitis B virus infection in mice[J]. Front Cell Infect Microbiol, 2022, 12: 844132. DOI: 10.3389/fcimb.2022.844132.
[38]	Wang J, Wang Y, Zhang X, et al. Gut microbial dysbiosis is associated with altered hepatic functions and serum metabolites in chronic hepatitis B patients[J]. Front Microbiol, 2017, 8: 2222. DOI: 10.3389/fmicb.2017.02222.
[39]	Yun Y, Chang Y, Kim HN, et al. Alterations of the gut microbiome in chronic hepatitis B virus infection associated with alanine aminotransferase level[J]. J Clin Med, 2019, 8(2): 173. DOI: 10.3390/jcm8020173.
[40]	Shen Y, Wu SD, Chen Y, et al. Alterations in gut microbiome and metabolomics in chronic hepatitis B infection-associated liver disease and their impact on peripheral immune response[J]. Gut Microbes, 2023, 15(1): 2155018. DOI: 10.1080/19490976.2022.2155018.
[41]	Bajaj JS. Alcohol, liver disease and the gut microbiota[J]. Nat Rev Gastroenterol Hepatol, 2019, 16(4): 235-246. DOI: 10.1038/s41575-018-0099-1.
[42]	Zhang D, Liu Z, Bai F. Roles of gut microbiota in alcoholic liver disease[J]. Int J Gen Med, 2023, 16: 3735-3746. DOI: 10.2147/IJGM.S420195.
[43]	Ciocan D, Voican CS, Wrzosek L, et al. Bile acid homeostasis and intestinal dysbiosis in alcoholic hepatitis[J]. Aliment Pharmacol Ther, 2018, 48(9): 961-974. DOI: 10.1111/apt.14949.
[44]	Smirnova E, Puri P, Muthiah MD, et al. Fecal microbiome distinguishes alcohol consumption from alcoholic hepatitis but does not discriminate disease severity[J]. Hepatology, 2020, 72(1): 271-286. DOI: 10.1002/hep.31178.
[45]	Wrzosek L, Ciocan D, Hugot C, et al. Microbiota tryptophan metabolism induces aryl hydrocarbon receptor activation and improves alcohol-induced liver injury[J]. Gut, 2021, 70(7): 1299-1308. DOI: 10.1136/gutjnl-2020-321565.
[46]	Philips CA, Pande A, Shasthry SM, et al. Healthy donor fecal microbiota transplantation in steroid-ineligible severe alcoholic hepatitis: a pilot study[J]. Clin Gastroenterol Hepatol, 2017, 15(4): 600-602. DOI: 10.1016/j.cgh.2016.10.029.
[47]	Philips CA, Phadke N, Ganesan K, et al. Corticosteroids, nutrition, pentoxifylline, or fecal microbiota transplantation for severe alcoholic hepatitis[J]. Indian J Gastroenterol, 2018, 37(3): 215-225. DOI: 10.1007/s12664-018-0859-4.
[48]	Bajaj JS, Gavis EA, Fagan A, et al. A randomized clinical trial of fecal microbiota transplant for alcohol use disorder[J]. Hepatology, 2021, 73(5): 1688-1700. DOI: 10.1002/hep.31496.
[49]	Wong VW, Ekstedt M, Wong GL, et al. Changing epidemiology, global trends and implications for outcomes of NAFLD[J]. J Hepatol, 2023, 79(3): 842-852. DOI: 10.1016/j.jhep.2023.04.036.
[50]	Shou D, Luo Q, Tang W, et al. Hepatobiliary and pancreatic: multi-donor fecal microbiota transplantation attenuated high-fat diet-induced hepatic steatosis in mice by remodeling the gut microbiota[J]. J Gastroenterol Hepatol, 2023, 38(12): 2195-2205. DOI: 10.1111/jgh.16359.
[51]	Zhou D, Pan Q, Shen F, et al. Total fecal microbiota transplantation alleviates high-fat diet-induced steatohepatitis in mice via beneficial regulation of gut microbiota[J]. Sci Rep, 2017, 7(1): 1529. DOI: 10.1038/s41598-017-01751-y.
[52]	Craven L, Rahman A, Nair Parvathy S, et al. Allogenic fecal microbiota transplantation in patients with nonalcoholic fatty liver disease improves abnormal small intestinal permeability: a randomized control trial[J]. Am J Gastroenterol, 2020, 115(7): 1055-1065. DOI: 10.14309/ajg.0000000000000661.
[53]	Xue L, Deng Z, Luo W, et al. Effect of fecal microbiota transplantation on non-alcoholic fatty liver disease: a randomized clinical trial[J]. Front Cell Infect Microbiol, 2022, 12: 759306. DOI: 10.3389/fcimb.2022.759306.
[54]	Famouri F, Shariat Z, Hashemipour M, et al. Effects of probiotics on nonalcoholic fatty liver disease in obese children and adolescents[J]. J Pediatr Gastroenterol Nutr, 2017, 64(3): 413-417. DOI: 10.1097/MPG.0000000000001422.
[55]	Schwabe RF, Greten TF. Gut microbiome in HCC - mechanisms, diagnosis and therapy[J]. J Hepatol, 2020, 72(2): 230-238. DOI: 10.1016/j.jhep.2019.08.016.
[56]	Huang H, Ren Z, Gao X, et al. Integrated analysis of microbiome and host transcriptome reveals correlations between gut microbiota and clinical outcomes in HBV-related hepatocellular carcinoma[J]. Genome Med, 2020, 12(1): 102. DOI: 10.1186/s13073-020-00796-5.
[57]	Sun L, Ke X, Guan A, et al. Intratumoural microbiome can predict the prognosis of hepatocellular carcinoma after surgery[J]. Clin Transl Med, 2023, 13(7): e1331. DOI: 10.1002/ctm2.1331.
[58]	Behary J, Amorim N, Jiang XT, et al. Gut microbiota impact on the peripheral immune response in non-alcoholic fatty liver disease related hepatocellular carcinoma[J]. Nat Commun, 2021, 12(1): 187. DOI: 10.1038/s41467-020-20422-7.
[59]	Ma C, Han M, Heinrich B, et al. Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells[J]. Science, 2018, 360(6391): eaan5931. DOI: 10.1126/science.aan5931.
[60]	Li Z, Zhang Y, Hong W, et al. Gut microbiota modulate radiotherapy-associated antitumor immune responses against hepatocellular carcinoma via STING signaling[J]. Gut Microbes, 2022, 14(1): 2119055. DOI: 10.1080/19490976.2022.2119055.
[61]	Hu C, Xu B, Wang X, et al. Gut microbiota-derived short-chain fatty acids regulate group 3 innate lymphoid cells in HCC[J]. Hepatology, 2023, 77(1): 48-64. DOI: 10.1002/hep.32449.
[62]	Spanu D, Pretta A, Lai E, et al. Hepatocellular carcinoma and microbiota: implications for clinical management and treatment[J]. World J Hepatol, 2022, 14(7): 1319-1332. DOI: 10.4254/wjh.v14.i7.1319.
[63]	Mao J, Wang D, Long J, et al. Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in hepatobiliary cancers[J]. J Immunother Cancer, 2021, 9(12): e003334. DOI: 10.1136/jitc-2021-003334.
[64]	Zheng Y, Wang T, Tu X, et al. Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma[J]. J Immunother Cancer, 2019, 7(1): 193. DOI: 10.1186/s40425-019-0650-9.
[65]	Lee PC, Wu CJ, Hung YW, et al. Gut microbiota and metabolites associate with outcomes of immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma[J]. J Immunother Cancer, 2022, 10(6): e004779. DOI: 10.1136/jitc-2022-004779.
[66]	Kao D, Roach B, Park H, et al. Fecal microbiota transplantation in the management of hepatic encephalopathy[J]. Hepatology, 2016, 63(1): 339-340. DOI: 10.1002/hep.28121.
[67]	Bajaj JS, Kakiyama G, Savidge T, et al. Antibiotic-associated disruption of microbiota composition and function in cirrhosis is restored by fecal transplant[J]. Hepatology, 2018, 68(4): 1549-1558. DOI: 10.1002/hep.30037.
[68]	Bajaj JS, Salzman N, Acharya C, et al. Microbial functional change is linked with clinical outcomes after capsular fecal transplant in cirrhosis[J]. JCI Insight, 2019, 4(24): e133410. DOI: 10.1172/jci.insight.133410.
[69]	Tun KM, Hong AS, Batra K, et al. A systematic review of the efficacy and safety of fecal microbiota transplantation in the treatment of hepatic encephalopathy and Clostridioides difficile infection in patients with cirrhosis[J]. Cureus, 2022, 14(5): e25537. DOI: 10.7759/cureus.25537.
[70]	Lazaridis KN, LaRusso NF. Primary sclerosing cholangitis[J].N Engl J Med, 2016, 375(12): 1161-1170. DOI: 10.1056/NEJMra1506330.
[71]	Tabibian JH, O’Hara SP, Trussoni CE, et al. Absence of the intestinal microbiota exacerbates hepatobiliary disease in a murine model of primary sclerosing cholangitis[J]. Hepatology, 2016, 63(1): 185-196. DOI: 10.1002/hep.27927.
[72]	Bajaj JS, Ann Hays R. Manipulation of the gut-liver axis using microbiome restoration therapy in primary sclerosing cholangitis[J]. Am J Gastroenterol, 2019, 114(7): 1027-1029. DOI: 10.14309/ajg.0000000000000191.
[73]	Philips CA, Augustine P, Phadke N. Healthy donor fecal microbiota transplantation for recurrent bacterial cholangitis in primary sclerosing cholangitis: a single case report[J]. J Clin Transl Hepatol, 2018, 6(4): 438-441. DOI: 10.14218/JCTH.2018.00033.
[74]	Allegretti JR, Kassam Z, Carrellas M, et al. Fecal microbiota transplantation in patients with primary sclerosing cholangitis: a pilot clinical trial[J]. Am J Gastroenterol, 2019, 114(7): 1071-1079. DOI: 10.14309/ajg.0000000000000115.
[75]	段建峰, 刘晓晨, 赵喜荣, 等. 经灌肠途径粪菌移植治疗复杂胆道术后胆瘘继发感染16例[J]. 中国现代普通外科进展, 2019, 22(11): 900-901, 904. DOI: 10.3969/j.issn.1009-9905.2019.11.018.
[76]	李胜兵, 刘海鸿, 黄潮, 等. 粪菌移植在临床治疗中的研究进展[J]. 中国微生态学杂志, 2019, 31(3): 352-355. DOI: 10.13381/j.cnki.cjm.201903023.
[77]	罗旭娟, 白雪, 李增晖, 等. 粪菌移植与中药大黄治疗高脂血症性急性胰腺炎大鼠模型的效果比较[J]. 临床肝胆病杂志, 2022, 38(12): 2767-2773. DOI: 10.3969/j.issn.1001-5256.2022.12.016.
[78]	黄瑞萍. 重症急性胰腺炎肠功能障碍病人粪菌移植治疗的护理[J]. 全科护理, 2017, 15(27): 3371-3372. DOI: 10.3969/j.issn.1674-4748.2017.27.014.
[79]	杨加琦. 追踪肿瘤局部免疫与肠道菌群动态演变探索胰腺癌免疫治疗优化策略[D]. 杭州: 浙江大学, 2020. DOI: 10.27461/d.cnki.gzjdx.2020.002120.
[80]	Nazmul Huda M, Kim M, Bennett BJ. Modulating the microbiota as a therapeutic intervention for type 2 diabetes[J]. Front Endocrinol, 2021, 12: 632335. DOI: 10.3389/fendo.2021.632335.
[81]	Wang Y, Yang Z, Tang H, et al. Faecal microbiota transplantation is better than probiotics for tissue regeneration of type 2 diabetes mellitus injuries in mice[J]. Arch Physiol Biochem, 2024, 130(3): 333-341. DOI: 10.1080/13813455.2022.2080229.
[82]	Wang H, Lu Y, Yan Y, et al. Promising treatment for type 2 diabetes: fecal microbiota transplantation reverses insulin resistance and impaired islets[J]. Front Cell Infect Microbiol, 2020, 9: 455. DOI: 10.3389/fcimb.2019.00455.
[83]	周迎, 李阳阳, 刘煜. 粪菌移植对非肥胖糖尿病小鼠发生1型糖尿病的影响及其机制探讨[J]. 中华医学杂志, 2022, 102(16):1224-1231. DOI: 10.3760/cma.j.cn112137-20210907-02043.
[84]	Plaza-Díaz J, Fontana L, álvarez-Mercado AI. Editorial: interplay between gut microbiota and the immune system in liver surgery and liver diseases[J]. Front Cell Infect Microbiol, 2023, 13: 1188092. DOI: 10.3389/fcimb.2023.1188092.
[85]	胥华泰, 应培均, 杨季红, 等. 肠道菌群对肝癌作用机制的研究进展[J]. 中国临床研究,2024, 37(6): 943-945. DOI: 10.13429/j.cnki.cjcr.2024.06.026.
[86]	周熙祥, 伍志伟, 张录梅, 等. 肠道菌群与肝癌的研究进展[J]. 中国微生态学杂志, 2021, 33(8): 971-975. DOI: 10.13381/j.cnki.cjm.202108022.
[87]	Janket SJ, Ackerson LK, Diamandis EP. Potential risks in fecal microbiota transplantation[J]. Clin Chem Lab Med, 2020, 58(4): e95. DOI: 10.1515/cclm-2019-1076.

Please choose a citation manager

Content to export